Igamad (Human Anti-D Immunoglobulin)

The immunoglobulin binds to any Rh(D) positive red blood cells that may enter the maternal circulation. This coating masks the D antigen, preventing the mother’s immune system from recognizing it and producing anti‑D antibodies. The result is a temporary, passive protection that averts maternal sensitization.

The dose of Igamad is determined by the prescribing clinician based on the specific clinical situation, such as the timing of exposure to fetal red cells and the mother’s Rh status. Healthcare providers follow established guidelines to select the appropriate amount for each patient.

Igamad is intended for use in pregnant women who are Rh‑negative, and it is administered under obstetric supervision. While it is not classified in a specific pregnancy category, the benefits of preventing severe fetal disease generally outweigh potential risks. Breastfeeding considerations should be discussed with a healthcare professional.

To order Igamad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Igamad contains Human Anti-D Immunoglobulin, the same active component found in other anti‑D preparations. Differences may lie in manufacturing processes, concentration, and regulatory approvals. Clinicians choose a product based on factors such as supply reliability, storage requirements, and compatibility with local guidelines.

Igamad must be stored at 2‑8 °C in a refrigerator, protected from light. It should not be frozen or shaken vigorously. Before use, inspect the vial for any particulate matter or discoloration and allow it to reach room temperature if required for intramuscular injection.

Igamad is given by intramuscular injection, typically into the deltoid or gluteal muscle. The injection should be performed by a qualified healthcare professional using aseptic technique. The exact site and volume depend on the prescribed dose and the patient’s clinical condition.

The most serious risks include severe allergic reactions such as anaphylaxis, hemolysis, thrombocytopenia, serum sickness‑like reactions, and rare coagulation disturbances like disseminated intravascular coagulation. Immediate medical attention is required if any signs of these reactions appear after administration.

Igamad should be avoided in individuals with a known severe allergy to human immunoglobulin preparations, those with IgA deficiency who have experienced anaphylaxis to IgA‑containing products, and patients for whom the risk of sensitization outweighs the benefit, as determined by a qualified clinician.